Review
Year 2023,
Volume: 40 Issue: 4, 792 - 794, 03.01.2024
Abstract
References
- 1. Hift RJ, Meissner PN.An analysis of 112 acute porphyric attacks in Cape Town, South Africa: evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity. Medicine (Baltimore) 2005; 84(1),48–60.
- 2. Aronson JK. Rare diseases and orphan drugs. British journal of clinical pharmacology 2006; 61(3):243.
- 3. https://www.resmigazete.gov.tr/ (Erişim tarihi: 14.03.2023)
- 4. Haffner ME. Adopting Orphan Drugs—Two Dozen Years of Treating Rare Diseases. New England Journal of Medicine 2006; 354(5): 445-7.
- 5. Hernberg-Ståhl E, Reljanović M. Orphan Drugs: Understanding the Rare Disease Market and its Dynamics. 2013:Woodhead Publishing.
- 6. Mitrano M. Liste-En-Sus Reform In France - What are The Consequences? Value in Health 2015; 18(7):A538.
- 7. Güzelalp Akdere C. Yetim İlaçlara Özel Fiyatlandırma ve Geri Ödeme Politikaları in İlaç ve Pazara Erişim Süreci (Kahveci R.ED.).2017. Sage Yayıncılık, Ankara p.196-206.
- 8. Schey C. Estimating the budget impact of orphan medicines in Europe: 2010-2020, Orphanet Journal of Rare Diseases 2011;6:62.
- 9. Schlander M. Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe, Expert Rev. Pharmacoecon. Outcomes Res.2014;1-9.
- 10. Hutchings A. Estimating the budget impact of orphan drugs in Sweden and France 2013-2020', Orphanet Journal of Rare Diseases 2014;9:22
- 11. Orphan Drugs Global Market Report 2023.
- 12. Ürek D, Karaman S. Önemli bir halk sağlığı sorunu olarak nadir hastalıklar ve yetim ilaçlar Hacettepe Sağlık İdaresi Dergisi 2019;2 (4):863-78 .
- 13. Senturk A, Demir O. Orphan Drug Market Analysis in Turkey.2016. Ispor
- 14. Koçkaya G, Atalay S, Oğuzhan G, Kurnaz M, Ökçün S, Sar Gedik Ç, Şaylan M, Şencan, N. Analysis of patient access to orphan drugs in Turkey. Orphanet journal of rare diseases 2021; 16(1), 68.
- 15. Oral M, Özçelikay G. Ethical overview of pharmaceutical industry policies in Turkey from various perspectives. Turk J Pharm Sci.2017; 14(3):264–73.
- 16. Koçkaya G, Wertheimer AI, Kılıç P, et al. An overview of the orphan medicines market in Turkey. Value Health Reg Issues 2014; 4:47–52.
Year 2023,
Volume: 40 Issue: 4, 792 - 794, 03.01.2024
Abstract
Drugs which have limited access and are used treat rare diseases, are called "orphan drugs".
The reason why these drugs are called "orphan" is that the pharmaceutical industry has little interest in developing and marketing these drugs which are used only for a low number of patient groups This is because pharmaceutical companies cannot compensate the very high cost of developing these drugs. In this review article it is aimed to give information about orphan drugs, policies about these drugs and difficulties to reach them.
Keywords
References
- 1. Hift RJ, Meissner PN.An analysis of 112 acute porphyric attacks in Cape Town, South Africa: evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity. Medicine (Baltimore) 2005; 84(1),48–60.
- 2. Aronson JK. Rare diseases and orphan drugs. British journal of clinical pharmacology 2006; 61(3):243.
- 3. https://www.resmigazete.gov.tr/ (Erişim tarihi: 14.03.2023)
- 4. Haffner ME. Adopting Orphan Drugs—Two Dozen Years of Treating Rare Diseases. New England Journal of Medicine 2006; 354(5): 445-7.
- 5. Hernberg-Ståhl E, Reljanović M. Orphan Drugs: Understanding the Rare Disease Market and its Dynamics. 2013:Woodhead Publishing.
- 6. Mitrano M. Liste-En-Sus Reform In France - What are The Consequences? Value in Health 2015; 18(7):A538.
- 7. Güzelalp Akdere C. Yetim İlaçlara Özel Fiyatlandırma ve Geri Ödeme Politikaları in İlaç ve Pazara Erişim Süreci (Kahveci R.ED.).2017. Sage Yayıncılık, Ankara p.196-206.
- 8. Schey C. Estimating the budget impact of orphan medicines in Europe: 2010-2020, Orphanet Journal of Rare Diseases 2011;6:62.
- 9. Schlander M. Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe, Expert Rev. Pharmacoecon. Outcomes Res.2014;1-9.
- 10. Hutchings A. Estimating the budget impact of orphan drugs in Sweden and France 2013-2020', Orphanet Journal of Rare Diseases 2014;9:22
- 11. Orphan Drugs Global Market Report 2023.
- 12. Ürek D, Karaman S. Önemli bir halk sağlığı sorunu olarak nadir hastalıklar ve yetim ilaçlar Hacettepe Sağlık İdaresi Dergisi 2019;2 (4):863-78 .
- 13. Senturk A, Demir O. Orphan Drug Market Analysis in Turkey.2016. Ispor
- 14. Koçkaya G, Atalay S, Oğuzhan G, Kurnaz M, Ökçün S, Sar Gedik Ç, Şaylan M, Şencan, N. Analysis of patient access to orphan drugs in Turkey. Orphanet journal of rare diseases 2021; 16(1), 68.
- 15. Oral M, Özçelikay G. Ethical overview of pharmaceutical industry policies in Turkey from various perspectives. Turk J Pharm Sci.2017; 14(3):264–73.
- 16. Koçkaya G, Wertheimer AI, Kılıç P, et al. An overview of the orphan medicines market in Turkey. Value Health Reg Issues 2014; 4:47–52.
There are 16 citations in total.
Details
| Primary Language | English |
|---|---|
| Subjects | Pharmacy Management |
| Journal Section | Review Articles |
| Authors | |
| Publication Date | January 3, 2024 |
| Submission Date | July 19, 2023 |
| Acceptance Date | October 10, 2023 |
| Published in Issue | Year 2023 Volume: 40 Issue: 4 |
Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.